2026 Q2 -tulosraportti
15 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenPEG gives a hint about whether a stock is expensive/cheap in relation to PE and growth. The further the number is above 1, the more expensive the stock is. And the further the number is below 1, the more the stock is a buy.
The numbers must be checked so that it doesn't become shit in, shit out. If you reverse the formula, you divide PE by PEG, then you get the growth. The growth should be in percent of the earnings, e.g. measured against next year. That gives Sandisk approximately 50% growth in earnings for next year. For Novo N, that gives 0,4% growth in earnings for next year. Is this correct? PE should be checked if it is correct. Nordnet's numbers don't always seem to be correct. The assumed growth is probably set by one or more analysts who may also be somewhat uncertain. PEG 1 should be neutral. I.e. that growth in earnings measured in percent corresponds to the PE. PE 20/20%growth = 1. That makes sense. One can accept a high valuation (PE) if the growth is high, as is normally the case in practice. A PE of 50/100%growth = PEG 0,5. = undervalued according to the PEG guide. But it probably becomes more uncertain the further into the future one looks, because no one can predict the future earnings with certainty.
·3 t sittenAugust 20 The UK's National Health Service (NHS) is launching the CURB trial, co-led by the University of Plymouth and University Hospitals Plymouth NHS Trust and funded by a £2.7 million grant from NIHR/MRC. From September 2026, the CURB trial will recruit 268 individuals with alcohol dependence, obesity, and chronic liver disease from diverse populations across England, Wales, and Scotland. Concurrently, the CRAVE trial (Cessation or Reduction of Alcohol Consumption in Veterans) is a nationwide Phase 3 clinical study initiated by the US Department of Veterans Affairs (VA). Its purpose is to investigate whether weekly injections of semaglutide, gradually increasing to a dose of up to 2.4 mg, can reduce heavy alcohol consumption and alcohol cravings in individuals with moderate to severe Alcohol Use Disorder (AUD). The simultaneous conduct of extensive trials with semaglutide by two major public health systems – the NHS in the UK and the VA in the USA – signals a potentially significant shift. Instead of solely using and marketing weight-loss medications, public health systems are now investigating whether semaglutide can also affect the brain mechanisms involved in addiction. According to the researchers: "If the trial [CURB] is successful, it is hoped that the drug can change the treatment of alcohol-related liver disease and obesity and help shape future treatment in the UK and the rest of the world."
·3 t sittenIs it just HR left after the big layoff rounds last year? I really think it's a bit of a wet dog of a company.
·4 t sitten · MuokattuHalleluja. Down again today. What a surprise 🙄🙄🙄 NOT I am currently down by 28.75 % and I have a lot 😪 Swings and roundabouts I know. Am gradually getting quite tired of 1.5 % up, 2 % down, week after week. The market value is falling where Trump's public statements naturally cause analysts to react. But oh my, how tiring it is.
"No cry at the casino" Didn't work either:) What about... No woman no cry!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
15 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenPEG gives a hint about whether a stock is expensive/cheap in relation to PE and growth. The further the number is above 1, the more expensive the stock is. And the further the number is below 1, the more the stock is a buy.The numbers must be checked so that it doesn't become shit in, shit out. If you reverse the formula, you divide PE by PEG, then you get the growth. The growth should be in percent of the earnings, e.g. measured against next year. That gives Sandisk approximately 50% growth in earnings for next year. For Novo N, that gives 0,4% growth in earnings for next year. Is this correct? PE should be checked if it is correct. Nordnet's numbers don't always seem to be correct. The assumed growth is probably set by one or more analysts who may also be somewhat uncertain. PEG 1 should be neutral. I.e. that growth in earnings measured in percent corresponds to the PE. PE 20/20%growth = 1. That makes sense. One can accept a high valuation (PE) if the growth is high, as is normally the case in practice. A PE of 50/100%growth = PEG 0,5. = undervalued according to the PEG guide. But it probably becomes more uncertain the further into the future one looks, because no one can predict the future earnings with certainty.
- ·3 t sittenAugust 20 The UK's National Health Service (NHS) is launching the CURB trial, co-led by the University of Plymouth and University Hospitals Plymouth NHS Trust and funded by a £2.7 million grant from NIHR/MRC. From September 2026, the CURB trial will recruit 268 individuals with alcohol dependence, obesity, and chronic liver disease from diverse populations across England, Wales, and Scotland. Concurrently, the CRAVE trial (Cessation or Reduction of Alcohol Consumption in Veterans) is a nationwide Phase 3 clinical study initiated by the US Department of Veterans Affairs (VA). Its purpose is to investigate whether weekly injections of semaglutide, gradually increasing to a dose of up to 2.4 mg, can reduce heavy alcohol consumption and alcohol cravings in individuals with moderate to severe Alcohol Use Disorder (AUD). The simultaneous conduct of extensive trials with semaglutide by two major public health systems – the NHS in the UK and the VA in the USA – signals a potentially significant shift. Instead of solely using and marketing weight-loss medications, public health systems are now investigating whether semaglutide can also affect the brain mechanisms involved in addiction. According to the researchers: "If the trial [CURB] is successful, it is hoped that the drug can change the treatment of alcohol-related liver disease and obesity and help shape future treatment in the UK and the rest of the world."
- ·3 t sittenIs it just HR left after the big layoff rounds last year? I really think it's a bit of a wet dog of a company.
- ·4 t sitten · MuokattuHalleluja. Down again today. What a surprise 🙄🙄🙄 NOT I am currently down by 28.75 % and I have a lot 😪 Swings and roundabouts I know. Am gradually getting quite tired of 1.5 % up, 2 % down, week after week. The market value is falling where Trump's public statements naturally cause analysts to react. But oh my, how tiring it is."No cry at the casino" Didn't work either:) What about... No woman no cry!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
15 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenPEG gives a hint about whether a stock is expensive/cheap in relation to PE and growth. The further the number is above 1, the more expensive the stock is. And the further the number is below 1, the more the stock is a buy.The numbers must be checked so that it doesn't become shit in, shit out. If you reverse the formula, you divide PE by PEG, then you get the growth. The growth should be in percent of the earnings, e.g. measured against next year. That gives Sandisk approximately 50% growth in earnings for next year. For Novo N, that gives 0,4% growth in earnings for next year. Is this correct? PE should be checked if it is correct. Nordnet's numbers don't always seem to be correct. The assumed growth is probably set by one or more analysts who may also be somewhat uncertain. PEG 1 should be neutral. I.e. that growth in earnings measured in percent corresponds to the PE. PE 20/20%growth = 1. That makes sense. One can accept a high valuation (PE) if the growth is high, as is normally the case in practice. A PE of 50/100%growth = PEG 0,5. = undervalued according to the PEG guide. But it probably becomes more uncertain the further into the future one looks, because no one can predict the future earnings with certainty.
- ·3 t sittenAugust 20 The UK's National Health Service (NHS) is launching the CURB trial, co-led by the University of Plymouth and University Hospitals Plymouth NHS Trust and funded by a £2.7 million grant from NIHR/MRC. From September 2026, the CURB trial will recruit 268 individuals with alcohol dependence, obesity, and chronic liver disease from diverse populations across England, Wales, and Scotland. Concurrently, the CRAVE trial (Cessation or Reduction of Alcohol Consumption in Veterans) is a nationwide Phase 3 clinical study initiated by the US Department of Veterans Affairs (VA). Its purpose is to investigate whether weekly injections of semaglutide, gradually increasing to a dose of up to 2.4 mg, can reduce heavy alcohol consumption and alcohol cravings in individuals with moderate to severe Alcohol Use Disorder (AUD). The simultaneous conduct of extensive trials with semaglutide by two major public health systems – the NHS in the UK and the VA in the USA – signals a potentially significant shift. Instead of solely using and marketing weight-loss medications, public health systems are now investigating whether semaglutide can also affect the brain mechanisms involved in addiction. According to the researchers: "If the trial [CURB] is successful, it is hoped that the drug can change the treatment of alcohol-related liver disease and obesity and help shape future treatment in the UK and the rest of the world."
- ·3 t sittenIs it just HR left after the big layoff rounds last year? I really think it's a bit of a wet dog of a company.
- ·4 t sitten · MuokattuHalleluja. Down again today. What a surprise 🙄🙄🙄 NOT I am currently down by 28.75 % and I have a lot 😪 Swings and roundabouts I know. Am gradually getting quite tired of 1.5 % up, 2 % down, week after week. The market value is falling where Trump's public statements naturally cause analysts to react. But oh my, how tiring it is."No cry at the casino" Didn't work either:) What about... No woman no cry!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt